Market Insights

Ribosomes as Drug Targets. The Quiet Rewrite of Psychiatry and Beyond. | Ep. 950

Therapeutics will be defined by translational pulse, not receptor binding.

Mar 5

Higher Cost of Capital. Tighter Private Biotech. | Ep. 944

How structural compression changed round size, timelines, and exits

Feb 26

The Public Playbook for Translating Science Into Therapeutics | Ep. 938

The Capital Markets Just Redefined What Translation Means

Feb 19

The Catalyst Machine | Ep. 931

How Capital Markets Quietly Rewired Translational Therapeutics

Feb 12

Liquidity Is the New Biology | Ep. 925

What the VC Data Quietly Says About the Future of Translational Biotech

Feb 5

Recycling Risk Capital | Ep. 918

Why 2026 Reopens Biotech and How Translation Wins

Jan 29

The Translation Reckoning | Ep. 912

Why 2025 quietly rewrote the rules of biotech and how 2026 will reward those who noticed

Jan 22

Reset Week in San Francisco | Ep. 906

Key Take Aways from This Years Conference

Jan 15

From Proof to Payoff | Ep. 900

How Biotech Translation Became a Capital Discipline in 2026

Jan 8

Biotech 2026. The Year Imagination Loses to Execution | Ep. 894

Why de-risked biology, operational clarity, and buyable assets will define the next cycle

Jan 1

Empty Labs, Full Signal | Ep. 888

How life sciences real estate quietly reveals where biotech really is and where it goes next

Dec 25, 2025

The Quiet Repricing of Risk | Ep. 882

What Today’s Private Biotech Tape Is Really Saying

Dec 18, 2025

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts